GYRE Stock Price | Gyre Therapeutics Inc. P/E, Revenue, EPS, & Forecasts

Gyre Therapeutics Inc. • GYRE

Capital at risk.

About
Metrics
Forecasts
Earnings performance
Financial performance
Sentiment analysis
FAQs

About Gyre Therapeutics Inc.

Ticker

GYRE

Trading on

NASDAQ

ISIN

US4037831033

Industry

Biotechnology

Sector

Healthcare

CEO

Headquarters

12770 High Bluff Drive, San Diego, CA, United States, 92130

Employees

579

Website

gyretx.com

Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY, under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573 is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.

Metrics

BasicAdvanced

Market cap

$761M

P/E ratio

197.5

EPS

$0.04

Dividend Yield

0.00%

Beta

7.07

Forward P/E ratio

76.34

EBIDTA

$14.4M

Ex dividend date

Price & volume

Market cap

$761M

Average daily volume

0.1M

90-day return

30-day return

7-day return

Dividends

Dividend per share

$0.00

Dividend yield

0.00%

Forward dividend per share

$0.00

Forward dividend yield

0.00%

Payout ratio

0.00%

Valuation

P/E ratio

197.5

Forward P/E

76.34

PEG ratio

Trailing P/E

197.5

Price to sales

7.09

Price to book

7.22

Earnings

EPS

$0.04

EPS estimate (current quarter)

-$0.02

EPS estimate (next quarter)

$0.00

EBITDA

$14.4M

Revenues (TTM)

$107M

Revenues per share (TTM)

$1.23

Technicals

Beta

7.07

52-week High

$14.42

52-week Low

$6.11

50-day moving average

$7.75

200-day moving average

$8.43

Short ratio

21.89

Short %

7.12%

Management effectiveness

ROE (TTM)

10.02%

ROA (TTM)

5.28%

Profit margin

6.20%

Gross profit margin

$102M

Operating margin

22.66%

Growth

Quarterly earnings growth (YoY)

166.20%

Quarterly revenue growth (YoY)

19.90%

Share stats

Outstanding Shares

96.3M

Float

20.5M

Insiders %

87.10%

Institutions %

3.44%

Analyst Insights & forecasts

100% Buy

0% Hold

0% Sell

Based on information from 1 analysts.

Average price target

$18.00

Earnings per share (EPS) forecast

windowbar_chart_4_bars

Actual

Expected

Surprise

-$0.00

$0.04

-102.75%

Q4 • 24Missed

$0.00

$0.03

-85.67%

Q1 • 25Missed

$0.00

$0.02

-89.00%

Q2 • 25Current

QuarterlyAnnual

Financial Performance

windowbar_chart_4_bars

Income StatementBalance SheetCash Flow

windowbar_chart_4_bars

Revenue

Net income

Profit margin

$26.8M

$0.4M

1.65%

Q2 • 25

$30.6M

$3.6M

11.81%

Q3 • 25

14.17%

716.74%

615.38%

QoQ growth

QuarterlyAnnual

Totals assets

Total liabilities

Debt to assets

$153M

$23.2M

15.20%

Q2 • 25

$159M

$22M

13.78%

Q3 • 25

4.41%

-5.32%

-9.32%

QoQ growth

QuarterlyAnnual

Operating

Investing

Financing

Free cash flow

$2.1M

$-3M

$22.4M

$1.8M

Q2 • 25

$4.7M

$-1.2M

$0.4M

$4M

Q3 • 25

123.95%

-59.01%

-98.37%

120.73%

QoQ growth

QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Gyre Therapeutics Inc. share?

Gyre Therapeutics Inc. shares are currently traded for undefined per share.

How many shares does Gyre Therapeutics Inc. have?

Gyre Therapeutics Inc. currently has 96.3M shares.

Does Gyre Therapeutics Inc. pay dividends?

No, Gyre Therapeutics Inc. doesn't pay dividends.

What is Gyre Therapeutics Inc. 52 week high?

Gyre Therapeutics Inc. 52 week high is $14.42.

What is Gyre Therapeutics Inc. 52 week low?

Gyre Therapeutics Inc. 52 week low is $6.11.

What is the 200-day moving average of Gyre Therapeutics Inc.?

Gyre Therapeutics Inc. 200-day moving average is $8.43.

Who is Gyre Therapeutics Inc. CEO?

The CEO of Gyre Therapeutics Inc. is -.

How many employees Gyre Therapeutics Inc. has?

Gyre Therapeutics Inc. has 579 employees.

What is the market cap of Gyre Therapeutics Inc.?

The market cap of Gyre Therapeutics Inc. is $761M.

What is the P/E of Gyre Therapeutics Inc.?

The current P/E of Gyre Therapeutics Inc. is 197.5.

What is the EPS of Gyre Therapeutics Inc.?

The EPS of Gyre Therapeutics Inc. is $0.04.

What is the PEG Ratio of Gyre Therapeutics Inc.?

The PEG Ratio of Gyre Therapeutics Inc. is null.

What do analysts say about Gyre Therapeutics Inc.?

According to the analysts Gyre Therapeutics Inc. is considered a buy.